Research library
Sources, with the status on the record.
Each row is a paper or a ClinicalTrials.gov entry checked on 21 November 2026. Titles are the authors’ or the registry’s words. Nalen Lab does not restate them as claims about these products. A registration is not a result.
Records checked 2026-11-21. Open registry rows in this view: 0. Selank has published papers and no verified intervention trial.
Loading filters…
CJC-1295 without DAC
2006
Publication
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Teichman SL et al. · Journal of Clinical Endocrinology & Metabolism
PublishedDifferent form from the catalogue listing
This study used long-acting CJC-1295 (the DAC form). The without-DAC catalogue listing is a different molecule. The same paper is also filed under CJC-1295 with DAC.
View in the catalogueCJC-1295 without DAC
2009
Publication
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.
Sackmann-Sala L et al. · Growth Hormone & IGF Research
PublishedDifferent form from the catalogue listing
Long-acting (DAC) analogue. Filed under the without-DAC listing as a different form, and under the with-DAC listing as the same form.
View in the catalogueCJC-1295 without DAC
2005
Registry
A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity
Phase 2 · ClinicalTrials.gov · NCT00267527 · ConjuChem
TerminatedDifferent form from the catalogue listing
Terminated. The sponsor's CJC-1295 programme used the long-acting DAC form, not Mod GRF 1–29. Also filed under CJC-1295 with DAC.
View in the catalogue